Supplementary Figure 3 from Persistence of Drug-Resistant Leukemic Stem Cells and Impaired NK Cell Immunity in CML Patients Depend on MIR300 Antiproliferative and PP2A-Activating Functions

Autor: Danilo Perrotti, Bruno Calabretta, Maria R. Baer, Xiaoxuan Fan, Ying Zou, Katerina Machova Polakova, Jianfei Qi, Guido Marcucci, Jane F. Apperley, Dragana Milojkovic, Francesco Dazzi, Christopher Harman, Garrett Fitzgerald, Michael W. Deininger, Peter Hokland, Martin Guimond, Moutuaata M. Moutuou, Denis-Claude Roy, Ramiro Garzon, Alistair G. Reid, Philippa C. May, Georgios Nteliopoulos, Paolo Vigneri, Fabio Stagno, Catriona H. M. Jamieson, Gabriel Pineda, Carlo Gambacorti-Passerini, Klara Srutova, Bin Zhang, Christopher J. Walker, Ann-Kathrin Eisfeld, Shuzhen Wang, Paolo Neviani, Jason G. Harb, Justin J. Ellis, Lorenzo Stramucci, Rossana Trotta, Giovannino Silvestri
Rok vydání: 2023
DOI: 10.1158/2643-3230.22363967.v1
Popis: Figure S3. MIR300 acts as master PP2A activator and inhibitor of G1/S transition. A, (left) Additional effects of MIR300 on SET, CCND2 and CDK6 expression; (right) KEGG/GO analysis of MIR300 effects on signal transduction pathways. B, CSmiRTar (filters: bone marrow normal and myeloid leukemia cells) and miRDIP-ComiR integrated analyses show functional clustering of predicted/validated MIR300 targets.
Databáze: OpenAIRE